Skip to content

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
- Overview
- Pipeline
Contact

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
- Overview
- Pipeline
Contact

Oncology

Phase II Investigation of TVB-2640 (denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma

By Graviton / 04/2023

Clinical Cancer Research

Combination of fatty acid synthase inhibitor with tyrosine kinase inhibitors shows synergistic efficacy in HCC preclinical models, a novel potential approach for clinical development

By Graviton / 02/2023

HCC-TAG

Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer

By Graviton / 07/2022

Nature Communications

Therapeutic efficacy of FASN inhibition in preclinical models of HCC

By Graviton / 01/2022

Hepatology

First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

By Graviton / 04/2021

EClinicalMedicine

TVB-2640 with Bevacizumab in Relapsed High-grade Astrocytoma

By Graviton / 09/2020

European Society for Medical Oncology (ESMO) Congress

Updated Results from a Prospective Phase 2 Study in Patients with First Relapse of High-grade Astrocytoma Using TVB-2640 in Combination with bevacizumab

By Graviton / 06/2019

ASCO

FASN inhibition as a potential treatment for therapy of endocrine resistant breast cancer

By natalia / 12/2018

San Antonio Breast Cancer Symposium

Updated results from a prospective, randomized phase 2 study in patients with first relapse of high-grade astrocytoma using TVB-2640 in combination with Avastin versus Avastin alone

By natalia / 11/2018

Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology

Fatty acid synthase inhibitor TVB-3664 reverses multiple components of diet-induced nonalcoholic steatohepatitis in mice treated with or without co-administered pirfenidone and reduces collagen accumulation in bleomycin-induced murine skin fibrosis

By Graviton / 10/2017

AASLD

Post pagination

1 2 … 4 Next →

Site map

About
Science
Investors
Programs
Contact

About
Science
Investors
Programs
Contact

Contact us

Business Development
bd@sagimet.com

Investors
ir@sagimet.com

Media
media@sagimet.com

Human Resources
hr@sagimet.com

© 2024 Sagimet Biosciences. All Rights Reserved. Terms of Use Agreement | Privacy Policy | Clinical Trial Privacy Notice

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
- Overview
- Pipeline
Contact

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
- Overview
- Pipeline
Contact

Scroll to Top